Stockscreener 앱 받기
1.14
4.20%
-0.05
시간 외 거래:
1.15
0.01
+0.88%
전일 마감가:
$1.19
열려 있는:
$1.21
하루 거래량:
271.83K
Relative Volume:
0.49
시가총액:
$51.45M
수익:
$1.49M
순이익/손실:
$-12.27M
주가수익비율:
-3.4379
EPS:
-0.3316
순현금흐름:
$-11.30M
1주 성능:
-10.94%
1개월 성능:
-26.45%
6개월 성능:
+14.00%
1년 성능:
-2.56%
1일 변동 폭
$1.14
$1.22
1주일 범위
$1.09
$1.32
52주 변동 폭
$0.7006
$2.59
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.14 | 51.45M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
A director receives 55,924 RenovoRx (RNXT) stock options exercisable at $1.55 per share. - Stock Titan
A director receives 55,924 RenovoRx (RNXT) stock options with a $1.55 exercise price. - Stock Titan
55,924 options with a $1.55 exercise price go to RenovoRx (RNXT) director Robert J. Spiegel. - Stock Titan
RenovoRx (RNXT) grants Laurence Marton 55,924 stock options with a $1.55 exercise price. - Stock Titan
CFO of RenovoRx (RNXT) awarded 80,000 RSUs - Stock Titan
RenovoRx Inc. (RNXT) Falls 6.15% to $2.24 as Stock Approaches Key Support LevelCommon Gap - careplusvn.com
$RenovoRx (RNXT.US)$ - Moomoo
$RenovoRx (RNXT.US)$ - Moomoo
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - Investing News Network
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline - Yahoo Finance
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - Yahoo Finance
Biotech Stocks At 52-Week HighsRNXT +15%, EOLS, CRNX, APGE - RTTNews
RenovoRx publishes pharmacokinetic data from Phase III trial By Investing.com - Investing.com Canada
RenovoRx publishes pharmacokinetic data from Phase III trial By Investing.com - Investing.com UK
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - Investing News Network
Transcript : RenovoRx, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
RenovoRx (RNXT) Earnings Update: Reported EPS Tops Expectations at the Close; Post-Report: The Stock Finishes Near Unchanged in the Latest SessionShort-Term Outlook - vinanet.vn
RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update - Kalkine Media
RenovoRx regains Nasdaq minimum bid price compliance - Investing.com
RenovoRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com UK
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo! Finance Canada
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price - The Globe and Mail
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Investing News Network
RenovoRx receives U.S. patent allowance for cancer device - Investing.com
RenovoRx receives U.S. patent allowance for cancer device By Investing.com - Investing.com Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment - marketscreener.com
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - The Manila Times
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price - TipRanks
RenovoRx Advances Targeted Localized Therapy for Advanced Pancreatic Cancer - geneonline.com
HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - sharewise.com
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - Yahoo Finance
RenovoRx (RNXT) Q2 2026 Earnings: Narrower-than-Expected Loss Drives 11% Share RallyForward Guidance Trends - vinanet.vn
RNXT Q2 2026 Earnings: Narrower Loss Beats Estimate, Shares Jump 11%Share Dilution Risk - vinanet.vn
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - Kalkine
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Canada
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx Q2 Earnings Call Highlights - Yahoo Finance
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Renovorx Inc 주식 (RNXT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Jan 21 '26 |
Buy |
1.00 |
10,000 |
9,975 |
798,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
4.22%
자본화:
|
볼륨(24시간):